Should I Stop Taking HRT If I Have Fibroids?

Having fibroids does not automatically mean you need to stop hormone replacement therapy. Research on HRT and uterine fibroids in menopausal women shows variable effects on fibroid size, and the consensus among gynecologists leans toward continuing treatment with appropriate monitoring rather than stopping outright. The answer depends on specifics: the type of HRT, the route it’s delivered, the dose, and how your fibroids respond over time.

Why Fibroids and HRT Are Connected

Uterine fibroids are benign growths in the muscular wall of the uterus, and they are sensitive to reproductive hormones. Progesterone in particular drives fibroid cell growth by switching on several pathways that promote cell proliferation.¹ Estrogen also plays a role, helping to maintain the blood supply and cellular environment that keeps fibroids alive. This is why fibroids tend to shrink after menopause: the natural decline in both hormones pulls the rug out from under them.²

HRT reintroduces the very hormones that fibroids feed on. This is where the concern comes from, and it’s a legitimate one. But “reintroduces” does not mean “restores to premenopausal levels.” HRT doses are generally much lower than the hormonal concentrations your body produced during your reproductive years, and the effects on fibroids are usually proportionally modest. A review of the literature found that the effects of hormone therapy on fibroid volume and size in menopausal women were variable rather than uniformly harmful.³

What Happens to Fibroids When You Start HRT

One of the clearest long-term studies tracked postmenopausal women with fibroids over three years, comparing those on HRT with those not taking it. Both groups actually saw some fibroid growth in the first year. By the second year, growth continued to be significant only in HRT users. By the third year, though, fibroid volume in HRT users had started to decline, and in the control group fibroids had returned close to their baseline size.⁴ At the end of three years, only about three out of 34 HRT users had fibroid growth exceeding 25 percent over their starting volume. That’s a small minority.

Other studies using combined estrogen-progestin regimens have found similar patterns: fibroids might increase slightly in volume, but often without reaching statistical significance compared to baseline. One study following 60 menopausal patients on transdermal estradiol plus a progestin for 12 months found that average fibroid volume went from about 24 to 29 cubic centimeters, a modest change that was not statistically significant.⁵ The picture across the research is one of mild, often temporary growth rather than dramatic enlargement.

Why the Delivery Route Matters More Than You’d Think

One of the more surprising findings in this area is that how HRT is delivered to your body can matter as much as which hormones you take. A study comparing oral estrogen pills with transdermal patches found no significant change in fibroid size in the oral group after one year, but a significant increase in the transdermal group.⁶

A separate analysis reinforced the gap: fibroids in women using oral estrogen showed no change in nearly half of patients, whereas in the transdermal group only about 10 percent of patients had stable fibroids, with up to half seeing enlargement within six months.⁵ This likely comes down to differences in how estrogen is processed. Oral estrogen passes through the liver first, which converts a portion of it into less biologically active forms before it reaches the uterus. Transdermal delivery bypasses the liver, delivering more active hormone directly into the bloodstream and, consequently, to fibroid tissue.

This doesn’t mean patches are always worse. For women without fibroids, transdermal delivery has advantages: lower risk of blood clots, steadier hormone levels, and fewer metabolic side effects. But if you have fibroids and your doctor is choosing between routes, the oral path may be preferable from a fibroid-growth standpoint. It’s the kind of nuance that gets lost when the discussion is framed as a simple yes-or-no question about whether to stop HRT entirely.

The Progestin Problem

Most women with an intact uterus who take estrogen also need a progestin to protect the uterine lining from thickening unchecked. This is important for preventing endometrial cancer, but it creates a tension when fibroids are present, because progesterone is arguably the more powerful of the two hormones when it comes to stimulating fibroid growth.¹

Not all progestins behave identically. Synthetic progestins differ in their binding profiles and how strongly they activate the pathways that drive fibroid cell proliferation. Some clinicians prefer formulations that use micronized progesterone, which is bioidentical to what the body produces, though the evidence that it is meaningfully gentler on fibroids than synthetic alternatives is still limited. The type of progestin, the dose, and whether it’s taken continuously or in a cyclical pattern can all influence how fibroids respond.

For women whose fibroids seem especially sensitive to progestin, one option is a levonorgestrel-releasing intrauterine system, which delivers progestin locally to the uterine lining while minimizing systemic exposure. This allows estrogen to be taken for menopausal symptom relief without as much progestin circulating to the fibroids. It’s not a universal fix, but it’s one of several adjustments a prescriber can make before resorting to stopping HRT.

When Vaginal Estrogen Is All You Need

Many women going through menopause find that their most bothersome symptoms are genitourinary: vaginal dryness, painful sex, urinary urgency, recurrent infections. If those are your primary complaints rather than hot flashes or mood disturbance, you may not need systemic HRT at all. Low-dose vaginal estrogen products deliver small amounts of estradiol directly to vaginal tissue, and pharmacokinetic studies have shown that these doses do not raise estrogen levels in the blood above baseline values.⁷

Because the estrogen stays local rather than circulating systemically, there is very little reason to worry about fibroid stimulation. If your fibroids are small, asymptomatic, and your menopause symptoms are mainly below the belt, vaginal estrogen could be a way to get relief without touching your fibroids at all. This is worth raising with your doctor if the conversation has been framed around systemic HRT as the only option.

Newer Formulations and Tissue-Selective Approaches

Pharmaceutical development has been moving toward therapies that target estrogen receptors differently in different tissues. The idea is to deliver estrogen’s benefits where you want them (bone, brain, vaginal tissue) while minimizing stimulation where you don’t (breast, uterus). One such combination pairs an estrogen with a selective estrogen receptor modulator. In women who switched to this type of formulation, imaging of existing fibroids showed no change in most cases.⁸

These options are still relatively niche and may not be available or appropriate for every patient. But they represent a growing understanding that the question isn’t just “hormones or no hormones” but rather “which hormones, how much, and delivered where.” For women with fibroids who are struggling on conventional HRT, asking about tissue-selective formulations is a reasonable conversation to have with a prescriber who stays current with the literature.

Monitoring Is the Real Safety Net

The strongest practical recommendation that emerges from the research isn’t to avoid HRT if you have fibroids, but to use the lowest effective dose and undergo regular surveillance.⁹ In practice, that means getting a baseline pelvic ultrasound before starting or continuing HRT, so you know exactly what size your fibroids are and where they sit. Repeat ultrasounds at regular intervals (typically every six to 12 months in the first year or two, then annually if things are stable) let you and your doctor catch meaningful growth early.

“Meaningful growth” is the key phrase. A fibroid that grows a few millimeters on ultrasound is not necessarily a problem. What matters is the trend, the speed of growth, and whether you develop new symptoms like bleeding, pelvic pressure, or pain. A fibroid that was quietly sitting there before HRT and grows modestly without causing trouble does not, by itself, require you to stop treatment.

When You Should Genuinely Be Concerned

There are situations where fibroid behavior on HRT warrants real attention. Any new lesion appearing in the uterus after menopause, or rapid growth of an existing fibroid, needs to be investigated. This isn’t just about discomfort. Although it’s rare, a rapidly growing uterine mass after menopause can occasionally turn out to be a leiomyosarcoma, a type of cancer, rather than a benign fibroid.¹⁰ The overwhelming majority of growing fibroids on HRT are still benign, but the possibility is why monitoring matters.

You should also take seriously any new or worsening symptoms. If you start HRT with small, asymptomatic fibroids and then develop heavy or irregular bleeding, increasing pelvic pain, or a sensation of fullness or pressure in the lower abdomen, those are signs that the fibroids may be responding to the hormonal stimulus in a clinically relevant way. That doesn’t automatically mean you stop HRT, but it does mean your doctor should re-evaluate. Sometimes adjusting the dose, changing the progestin, or switching the delivery route resolves the issue. Other times, stopping or pausing HRT for a period and repeating imaging is the safer course.

Making the Decision Personal

The trade-off ultimately comes down to how much HRT is helping you versus how your fibroids are behaving. For a woman with severe hot flashes, insomnia, and joint pain who has small, stable, asymptomatic fibroids, continuing HRT with monitoring is straightforward. The benefits clearly outweigh the modest risk of mild fibroid growth. For a woman whose symptoms are manageable and whose fibroids are already large or causing bleeding, the calculus shifts. Your doctor should be tailoring this conversation to your situation rather than applying a blanket rule.

There’s also a time dimension worth considering. Many women use HRT for a defined period during the worst of their menopausal symptoms and then taper off. If your fibroids grow somewhat during a couple of years on HRT, they’re likely to shrink again once you stop. The three-year study mentioned earlier showed exactly that pattern: even the HRT group’s fibroid volumes started to plateau and decline by the third year.⁴ Fibroids after menopause are fundamentally a waning problem, and a short stint on HRT is unlikely to reverse that trajectory permanently.

Racial Disparities in Fibroid Burden

The conversation about fibroids and HRT doesn’t happen in a vacuum, and it hits some women harder than others. Black women have a consistently higher prevalence and greater severity of uterine fibroids compared to white women, with the difference documented across multiple populations and study designs.¹¹ Fibroids tend to appear earlier, grow larger, and cause more symptoms in Black women. This means the question of HRT and fibroids may be more common and more pressing in this population, yet the clinical trials on HRT and fibroids have not always reflected that demographic reality.

If you’re in a higher-risk group for fibroids, the general advice about monitoring becomes even more important. Starting with lower doses, getting ultrasounds at slightly shorter intervals, and staying alert to symptom changes gives your doctor the information needed to course-correct early. The underlying principle is the same for everyone: don’t stop HRT reflexively, but don’t ignore what the fibroids are doing either.

Procedural Options If Fibroids Become Unmanageable

For women who want to stay on HRT but find their fibroids are growing beyond what monitoring and dose adjustments can manage, there are procedural interventions that deal with the fibroids themselves rather than forcing a choice between fibroids and hormone relief. Uterine fibroid embolization, a minimally invasive procedure that cuts off blood supply to fibroids, can shrink them without surgery. Myomectomy removes fibroids while leaving the uterus intact. And for women who are done with any considerations about their uterus, hysterectomy eliminates the fibroid problem entirely and also removes the need for a progestin in HRT, since there’s no longer a uterine lining to protect.

These are not first-line approaches for most menopausal women with small fibroids, and they carry their own risks and recovery times. But knowing they exist changes the framing. The question isn’t really “should I stop HRT because of fibroids” so much as “what’s the best strategy to manage both my menopausal symptoms and my fibroids at the same time?” For most women, that strategy starts with choosing the right type, dose, and route of HRT; continues with regular ultrasound monitoring; and reserves procedural intervention for the minority of cases where fibroids grow significantly or become symptomatic despite adjustments.